tetano
Editor, Senior Moderator
Front Allergy
. 2021 Oct 1;2:733466.
doi: 10.3389/falgy.2021.733466. eCollection 2021.
A Case of Acute Pericarditis After COVID-19 Vaccination
Andrea Sonaglioni[SUP] 1 [/SUP], Adriana Albini[SUP] 2 [/SUP], Douglas M Noonan[SUP] 2 3 [/SUP], Antonio Brucato[SUP] 4 [/SUP], Michele Lombardo[SUP] 1 [/SUP], Paola Santalucia[SUP] 1 [/SUP]
Affiliations
Abstract
A two-dose regimen of Pfizer-BioNTech COVID-19 vaccination confers 95% protection against COronaVIrus Disease 19 (COVID-19) and the safety profile is adequate. To the submission date, there were no reports in literature of acute pericarditis after BNT162b2 vaccination. However, pericarditis has been reported as a rare event associated with COVID-19 infection, which could be due to the pro-inflammatory effects of the spike protein. Recent evidence of post-vaccine myocarditis has been published. Herein we describe the case of a middle-aged healthy women who developed symptoms and signs of acute pericarditis 7-10 days after the second dose of Pfizer-BioNTech COVID-19 vaccination. Although a direct effect cannot be stated, it is important to report a potential adverse vaccine reaction effect that could be associated with the expression of SARS-CoV-2 spike protein induced from the mRNA of the vaccine.
Keywords: COVID-19; Pfizer-BioNTech; SARS-CoV-2; acute pericarditis; vaccination.
. 2021 Oct 1;2:733466.
doi: 10.3389/falgy.2021.733466. eCollection 2021.
A Case of Acute Pericarditis After COVID-19 Vaccination
Andrea Sonaglioni[SUP] 1 [/SUP], Adriana Albini[SUP] 2 [/SUP], Douglas M Noonan[SUP] 2 3 [/SUP], Antonio Brucato[SUP] 4 [/SUP], Michele Lombardo[SUP] 1 [/SUP], Paola Santalucia[SUP] 1 [/SUP]
Affiliations
- PMID: 35387019
- PMCID: PMC8974729
- DOI: 10.3389/falgy.2021.733466
Abstract
A two-dose regimen of Pfizer-BioNTech COVID-19 vaccination confers 95% protection against COronaVIrus Disease 19 (COVID-19) and the safety profile is adequate. To the submission date, there were no reports in literature of acute pericarditis after BNT162b2 vaccination. However, pericarditis has been reported as a rare event associated with COVID-19 infection, which could be due to the pro-inflammatory effects of the spike protein. Recent evidence of post-vaccine myocarditis has been published. Herein we describe the case of a middle-aged healthy women who developed symptoms and signs of acute pericarditis 7-10 days after the second dose of Pfizer-BioNTech COVID-19 vaccination. Although a direct effect cannot be stated, it is important to report a potential adverse vaccine reaction effect that could be associated with the expression of SARS-CoV-2 spike protein induced from the mRNA of the vaccine.
Keywords: COVID-19; Pfizer-BioNTech; SARS-CoV-2; acute pericarditis; vaccination.